Drug Profile
Research programme: anti-RANKL monoclonal antibodies - Pyxis Oncology/Epitomics
Alternative Names: APX 008Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Epitomics
- Developer Pyxis Oncology
- Class Monoclonal antibodies
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 28 Jul 2018 No recent reports of development identified for preclinical development in Bone-disorders in USA (Parenteral)
- 20 Mar 2014 Preclinical development is ongoing in USA